 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 Nuvalent Presents New...

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Leerink more bullish on Nuvalent, upgrades to Outperform

Leerink gets more bullish on Nuvalent, upgrades shares

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 22,000 shares of the business's stock in a transaction dated Thursday, March 28th. The stock was sold at an average...

Deborah Ann Miller Sells 22,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock

Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)

Nuvalent, Inc. (NASDAQ:NUVL  Get Free Report) has been given a consensus recommendation of Moderate Buy by the nine brokerages that are covering the firm, MarketBeat.com reports...

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Moderate Buy" by Brokerages

Ellsworth Advisors LLC trimmed its position in shares of Nuvalent, Inc. (NASDAQ:NUVL  Free Report) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the...

Ellsworth Advisors LLC Sells 515 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

Nuvalent, Inc. (NASDAQ:NUVL  Get Free Report) insider Darlene Noci sold 20,000 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $77.51...

Nuvalent, Inc. (NASDAQ:NUVL) Insider Darlene Noci Sells 20,000 Shares

Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Volume (M)	624,439.00
52-Wk High	$89.39
52-Wk Low	$32.06

NUVL Nuvalent Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals